CREATE Medicines Raises $122M in New Funding Round

Why It Matters

The infusion of capital accelerates clinical development, potentially expanding CAR‑T therapy into solid tumors and autoimmune conditions and reshaping oncology and immunology markets.

Key Takeaways

• $122M raised to fund CAR‑T trials for solid tumors
• Rebranded from Myeloid Therapeutics to CREATE Medicines
• Expanding pipeline now includes autoimmune disease programs
• Investors include Newpath, ARCH, and Hatteras Venture Partners
• Founder Siddhartha Mukherjee brings oncology expertise to leadership

Pulse Analysis

Chimeric antigen receptor T‑cell (CAR‑T) therapy has transformed blood‑cancer treatment, but extending the approach to solid tumors remains a scientific hurdle. CREATE Medicines, the rebranded Myeloid Therapeutics, is betting on myeloid‑derived CAR‑T cells to overcome the immunosuppressive tumor micro‑environment. By leveraging a cell type that naturally infiltrates solid tissue, the company hopes to achieve deeper tumor penetration and durable responses. This strategic shift mirrors a broader industry trend where innovators seek next‑generation CAR‑T platforms capable of tackling the most prevalent cancers.

The latest $122 million financing round underscores investor confidence in CREATE’s dual‑track strategy. Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners—each with a track record of backing breakthrough immunotherapies—joined existing backers to close the round. In a market where CAR‑T start‑ups routinely raise $50‑100 million per series, the size of this round signals that the venture community believes CREATE can clear pre‑clinical hurdles and move swiftly into Phase 1 trials. The capital will fund GMP manufacturing, regulatory filings, and early‑stage clinical sites across the United States.

If CREATE’s myeloid‑CAR‑T candidates demonstrate safety and efficacy, the company could open a new therapeutic class for both oncology and autoimmune disorders. Successful solid‑tumor data would attract partnership offers from major pharmaceutical firms seeking to diversify their immuno‑oncology portfolios. Moreover, the autoimmune pipeline could position CREATE as a rare biotech with cross‑indication relevance, potentially accelerating revenue streams beyond the typical CAR‑T timeline. Analysts therefore view the funding as a catalyst that may reshape competitive dynamics and expand the overall addressable market for cell‑based therapies.

Deal Summary

Biotech firm CREATE Medicines, formerly Myeloid Therapeutics, announced it has raised $122 million from investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners to advance its CAR‑T therapy pipeline. The funding will support human trials for its first CAR‑T candidates and expansion into autoimmune disease research.